FDA approves Bayer's novel stroke-prevention drug, first in class

The FDA approved Bayer's new drug, the first in a novel class designed to prevent blood clots without raising bleeding risk, for reducing stroke recurrence. This marks a potential shift in anticoagulation therapy, though long-term safety and real-world efficacy remain to be seen. The approval could impact stroke management protocols and Bayer's market position.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works